The Impact of Late Effects After Treatment for Bladder Cancer on Quality of Life (CONQUER)

March 2, 2026 updated by: Jørgen Bjerggaard Jensen, Aarhus University Hospital

The Impact of Late Effects After Treatment for Bladder Cancer on Quality of Life - What is the Cost of the Cure?

Bladder Cancer prognosis, treatment, and subsequent morbidity and mortality vary between the different stages, thus resulting in a different impact on patients' lives. There are some well known late effects of the treatments for bladder cancer, but the knowledge of their impact on patients Quality of Life is sparse. This study aims to determine the prevalence of late effects impact on Quality of Life and potential risk factors for impairment.

Study Overview

Status

Enrolling by invitation

Conditions

Bladder Cancer

Study Type

Observational

Enrollment (Estimated)

2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Denmark
- - Aarhus N, Denmark, 8200
    - Department of Urology, Aarhus University Hospital
  - Gødstrup, Denmark, 7400
    - Department of Urology, Regional Hospital Gødstrup
  - Horsens, Denmark, 8700
    - Department of Urology, Regional Hospital Horsens
  - Randers, Denmark, 8900
    - Department of Urology, Regional Hospital Randers
  - Viborg, Denmark, 8800
    - Department of Urology, Regional Hospital Viborg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Sampling Method

Non-Probability Sample

Study Population

Patients over 18 years of age, referred due to hematuria

Description

Inclusion Criteria:

Patients are eligible if they are referred to a hospital in the Central Region Denmark, due to hematuria between 01/01/2022 and 01/01/2023
Ability to understand written and oral Danish

Exclusion Criteria:

Known Alzheimers disease
Diagnosed other causes explaining the hematuria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Health-related Quality of Life Time Frame: 5 years from baseline inclusion	Changes in Quality of Life measured using validated instruments	5 years from baseline inclusion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of late effects Time Frame: 5 years from baseline inclusion	Based on Patient Reported Outcomes and medical records	5 years from baseline inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Aarhus University Hospital

Collaborators

University of Aarhus

National Research Center for Survivorship and Late Adverse Effects Following Pelvic Organ Cancer, Denmark

Investigators

Principal Investigator: Jørgen Bjerggaard Jensen, Professor, Department of Urology, Aarhus University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2022

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

January 7, 2022

First Submitted That Met QC Criteria